The a-folate receptor (FR) is selectively overexpressed in 90% of nonmucinous ovarian carcinomas, whereas no expression is detectable in normal ovarian surface epithelium (OSE). Indirect evidence suggests that FR expression is associated with tumor progression and affects cell proliferation. To evaluate better the role of FR, we developed an approach based on intracellular expression of single-chain (sc) antibodies (intrabody) to downmodulate membrane expression of FR in ovary cancer cells. IGROV-1 and SKOV3 ovarian carcinoma cell lines were transfected with an anti-FR intrabody. Transfectants and parental cells were tested for FR, integrins and anti-FR intrabody expression by fluorescence-activated cell sorting (FACS), reverse transcription and polymerase chain reaction (RT-PCR) and/or immunoblotting. Cell growth characteristics and adhesion properties were evaluated in liquid, semisolid and organotypic cultures. The anti-FR scFv inhibited FR expression from 60 to 99%. At physiological concentrations of folate, proliferation varied directly as a function of FR expression. FR downmodulation was accompanied by reduced colonyforming ability in soft agar, morphological change of the cells, significant enhanced adhesion to laminin or Matrigel, a twoto three-fold increase in a6b4 integrin expression, and a marked reduction in laminin production. In three-dimensional organotypic cultures, anti-FR intrabody-transfected IGROV1 cells grew as a single-ordered layer, reminiscent of normal OSE growth in vivo. In conclusion, the anti-FR intrabody reverses the transformed phenotype in ovary cancer cells and may provide an efficient means to inhibit selectively the growth of these cells.
Introduction
Genetic engineering of antibodies has opened new avenues of therapeutic intervention 1 and the possibility to examine in detail the pathophysiological role of some cellular/tumor markers.
The use of intrabodies targeted to the endoplasmic reticulum (ER) has recently emerged as a highly efficient method to downregulate or ablate expression of a protein normally secreted or expressed on the cell surface. 2, 3 The stable introduction of a gene encoding intrabodies provides a powerful alternative to antisense RNA and other methods of gene inactivation. [3] [4] [5] The use of this method to functionally knockout proteins with a relevant role in oncologic processes has given rise to various phenotypic effects in tumor cells, including alterations consistent with the reversion of the malignant phenotype. 5, 6 Intrabodies are potentially suited for antiviral and antitumor gene therapy approaches, and preclinical and clinical studies have been promising. 7, 8 One of the more specific tumor markers identified in our laboratory 9 is the a-isoform of the folate receptor (FR), a 38-40 kDa glycosyl-phosphatidyl-inositol-anchored molecule [10] [11] [12] [13] that binds folic acid with high affinity. Detailed immunohistochemical analysis and evaluation of messenger RNA expression revealed moderate levels of FR expression on the cell surface of normal epithelial cells of kidney, lung and breast, and high levels in placental tissue.
9,14-17 FR is not expressed in normal ovarian surface epithelium (OSE) 18 but is selectively overexpressed in the vast majority of nonmucinous ovarian carcinomas, 9, 13 which arise from OSE. The association of FR expression with progression of the disease 13 has implicated this molecule in malignant transformation of this tissue. We recently showed that FR affects cell proliferation of ovarian carcinoma cells not only by mediating folate uptake but also by generating intracellular signals that are associated with dysregulated cell proliferation. 19 We also demonstrated that FR gene transcription is negatively affected by the induction of the tumor suppressor gene cav-1. 18 Two monoclonal antibody/ies (Mab), MOV18 and MOV19, directed to nonoverlapping epitopes of FR, have been generated in our laboratories. 9 These Mab, and their chimeric or bispecific derivatives, were entered in several diagnostic and therapeutic trials with some relevant clinical responses. 20, 21 To gain insight into the role of FR in ovarian cancer progression, we exploited the specificity of the anti FR MOV19 Mab to construct a single-chain (sc)Fv intrabody and tested the effects of functional downregulation of FR membrane expression on ovarian tumor cell proliferation and adhesion.
Results

Downregulation of FR by anti-FR intrabody expression
Fluorescence-activated cell sorting (FACS) analysis of IGROV-1, SKOV3 and CHO cells stably transfected with the MOV19 scFv intrabody construct and selected in G418-containing medium revealed heterogeneous expression of FR on the IGROV1 cell surface, whereas transfected SKOV3 and control transfected CHO cells were completely negative. Intact murine IgG Mab MOV19 that recognizes the same epitope of scFv intrabody and MOV18 that recognizes a nonoverlapping epitope were used for FR detection. No decrease in FR surface expression was detected in IGROV1 cells transfected with mock vector or irrelevant scFv as compared to wild-type cells (Figure 1a ). Similar analysis using single clones of transfected IGROV1 cells, obtained by limiting dilution, revealed a decrease in FR surface expression ranging from 50 to 100%. Three clones were identified that showed an average decrease in the mean fluorescence intensity (MFI) of 60710 (DM60), 8575 (DM85) and 9971 (DM99)%, respectively, in five repeated different experiments. Figure 1a reports a representative experiment. By contrast, several different clones isolated by limiting dilution of IGROV1 wild-type cells showed an MFI that varied less than 20% from that of the original mixed population (data not shown). The decrease in FR expression in intrabody-transfected cells was evident not only at the cell surface, but also in the whole-cell lysate as analyzed by Western blotting ( Figure  1b ). In agreement with the FACS analysis, the FR protein was undetectable in DM99, present in tiny amounts in DM85 and in larger amounts in DM60 as compared to the total FR protein produced by wild-type and mock cells.
Reverse transcription and polymerase chain reaction (RT-PCR) analysis of intracellular scFv mRNA expression in IGROV1 cells showed amplification in the control The almost total FR downmodulation observed in clone DM99 remained stable over time (1 year of culture), while after several months of culture DM60 and DM85 spontaneously displayed a further decrease in FR expression.
Effect of intrabody expression on cell growth
To test the biological effects of intrabody production, scFv-transfected cells, expressing or not expressing FR, were tested for possible alteration of physical parameters by FACS and for proliferation by cell counting. Even in the presence of detectable scFv intracellular expression, the physical parameters and the proliferative activity of scFv-transfected CHO cells (chosen as FR not expressing cells) were unchanged as compared to those of wild-type cells (data not shown). By contrast, analysis of proliferation in IGROV-1 cells growing in standard medium, which contains high folic acid concentrations, revealed two-to three-fold higher proliferation rates in IGROV-1 wild-type, irrelevant and mock-transfected cells than in Furthermore, we tested on transfected cells the cell surface expression of growth factor receptors previously described to affect cell proliferation. As assessed by FACS analysis, the levels of HER-1 (expressed at detectable levels) and HER-2 (expressed at threshold levels) were similar in wild-type, mock and anti-FR IGROV-1 transfected cells.
The progressive FR downmodulation observed in the three IGROV1 clones was also associated with decreased colony-forming ability (Figure 2b ). Indeed, clone DM60 displayed a growth pattern comparable to that of control cells, whereas clones DM85 and DM99 formed fewer colonies in soft agar. Clones plated at serial dilutions (starting from 2 Â 10 4 ) showed the same growth pattern, but DM85 and DM99 failed to grow when less than 1 Â 10 4 cells were plated.
Morphologic and adhesion alteration
IGROV1 cells transfected with the anti-FR scFv showed a decreased number of cells growing in suspension associated with an increase in cell size (Figure 3a) . By contrast, the anti-FR scFv had no effect on morphology of FR-negative CHO cells. In a short-term assay of adhesion to various extracellular matrix components (Figure 3b ), clones DM85 and DM99 showed significantly enhanced adhesion not only to untreated plastic wells but also to wells precoated with laminin or Matrigel, when To determine whether the variation in adhesion properties involved changes in the integrin pattern as well as in extracellular matrix components, expression of the integrin chains more widely distributed on epithelial cells and the laminin production were evaluated. As shown in Figure 3d for wild-type, mock and DM99 cells, the expression of a6b4 chains, which were most consistently changed in anti-FR intrabody transfectants as compared to IGROV1 wild-type or mock-transfected cells, increased in proportion to the FR downmodulation. Consistent with the enhanced adhesion capability of DM99 cells, the FI was two to three times higher for both integrin chains as compared with mock transfectants and wild-type cells.
Moreover, Western blot analysis of the extracellular matrix revealed abundant production of laminin in IGROV1 wild-type and mock-transfected cells as compared to barely detectable levels in normal OSE cells, while anti-FR intrabody transfectants showed a marked reduction of laminin production (shown in Figure 3c for DM99 only), although levels were higher than in OSE cells.
Growth and phenotype in organotypic cultures
IGROV1 wild-type or mock-transfected grown for 10 days in three-dimensional organotypic cultures that mimic the growth of normal OSE cells showed multiple layers (7-10 cells in thickness) without a discernible pattern (shown for mock transfectants in Figure 4 , upper panel) whereas anti-FR intrabody transfectants exhibited a reduced number of layers and a more ordered pattern in direct relation with the level of FR downmodulation. In the case of DM99 (Figure 4, lower panel) , a singleordered layer of cells reminiscent of normal OSE growth in vivo was observed.
Discussion
Intrabodies targeted to the lumen of the ER provide a simple and effective means to inhibit the transport of plasma membrane proteins to the cell surface. The availability of an effective tool that inhibits the expression of FR on ovarian cancer cells enabled studies to Intrabody technology has been used to reduce the effective concentration and/or function of the target protein in different experimental models. 3 In our model, FR expression was almost completely abrogated and expression of the ER form of the anti-FR scFv was compatible with long-term viability of stably transfected cells, either expressing (IGROV1) or not expressing (CHO) the FR molecule, indicating that no toxicity is associated with intracellular retention of the scFv. The effects of FR downmodulation appeared to be specific, since the growth rate and anchorage-independent growth of transfectants but not that of control FRnegative cells was greatly impaired as compared to those of the parental cells.
The targeted ablation of expression of a single gene, such as the dominant oncogenes HER-2/neu or p21/ras, is sufficient to totally revert the malignant phenotype. 6, 22 Although FR is not yet recognized as an oncogeneencoded molecule, we observed a significant reversion of the malignant phenotype of IGROV1 ovarian carcinoma cells upon abrogation of FR, suggesting a relevant role of FR in the transformation/progression of this cancer. In medium with high folic acid concentrations, where passive diffusion and reduced folate carrier transport account in part for folate internalization, the reduced proliferation rate was not related to the level of expression. However, even in those conditions, the phenotype reversion of transfectants was correlated with FR downmodulation. These data further support our hypothesis that FR expression is related not only to proliferation control but also to progression of ovarian carcinoma. We previously showed that FR expression provides a growth advantage to FR-transfected cells in vitro and in vivo 23 and silences the expression of caveolin-1 in ovary carcinoma cells. 18 In our study focused on the analysis of the relation between caveolin-1 and FR, we have already demonstrated the re-expression of caveolin-1 and -2 as a consequence of intracellular FR sequestration by intrabodies in IGROV1 cells. 18 Since caveolin-1 acts as a negative regulator of signaling proteins in some normal cell types, 24 its re-expression on ovarian cancer cells might be partially responsible for restoration of growth control. Caveolin-1 re-expression might also be responsible for the acquired anchorage-dependent growth in NIH 3T3 cells 25 and in caveolin-1-transfected IGROV1 cells. 18 Cells with downmodulated FR expression exhibited a significant increase in a6b4 integrin expression and a drastic decrease in laminin production consistent with a reversion of the malignant phenotype. In many adult epithelial tissues, including OSE, adhesion of the cells to basement membrane requires the a6b4 and laminin-5 for integrity. a6b4 in normal ovaries is present only at the basal surface of the epithelial cells. 26 During progression of ovarian serous carcinoma, cells are frequently exfoliated from the ovary surface, consistent with an irregular distribution of a6b4 in tumors and a decrease in a6b4 expression in free-floating ascitic cells. 26 Laminin production and release from established ovarian cancer lines and ascitic cells is also highly increased compared to normal cells, 27 in keeping with the implication of this molecule in tumor cell migration and invasion. 28, 29 Studies regarding the absolute levels and pattern of expression of other integrins and cell adhesion molecules are in progress using both monolayer and organotypic cultures of anti-FR intrabody transfectants. These data (Figini et al, manuscript in preparation) should provide further insight into the role of FR in abnormal signaling and its interaction with other cell surface signaling molecules.
Several organotypic model systems have recently been established to accurately reflect in vivo growth. 30, 31 While monolayer cultures are suited for evaluation of growth rates, they do not recapitulate interactions with similar and different cell types of cells and with extracellular matrix. We placed the collagen bed at the air-medium interface since it more closely resembles normal ovary structure and discriminates tridimensional growth of normal OSE cells from that of immortalized OSE or malignant ovarian carcinoma lines. 31 FR downmodulated cells tended toward ordered growth in a single or few layers in tridimensional cultures, suggesting that the increase in a6b4 expression might lead to a restoration of the negative signaling of this integrin. 32 The inability of clone DM99 to form multilayers in organotypic culture, despite the high folic acid content in the medium, suggests a role for FR in cell de-differentiation rather than in cell proliferation. 
Both differentiation and apoptosis are possible mechanisms for the growth inhibition. Our data indicate that as a consequence of FR downmodulation, a reversion toward normal phenotype takes place suggesting differentiation as a major event, although a moderate increase of apoptosis was observed (data not shown).
In conclusion, the intracellular expression of an antibody that binds to FR in ovarian cancer cells holds the promise to help in elucidating the function of the target protein. Finally, these in vitro studies set the groundwork for in vivo preclinical development of selective novel strategies for the treatment of FR-overexpressing human cancers.
Materials and methods
Cell lines, primary cultures and antibodies
The following human tumor cell lines were used: ovarian carcinomas IGROV1 33 (gift from Dr J Bénard, Institute Gustave Roussy, Villejuif, France) and SKOV3 (provided by the American Type Culture Collection (ATCC)), which express FR at high and moderate levels, respectively, on the cell surface. 34 FR-negative CHO cells (ATCC) were used as controls. Unless stated otherwise, all lines were grown in RPMI-1640 medium (content of folic acid¼2.3 Â 10 3 nM) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine and 100 mg/ml streptomycin (standard medium) in a humidified 5% CO 2 atmosphere at 371C. Cells were routinely tested for mycoplasma contamination and were consistently negative.
Primary cultures of OSE were established as described 35 from nonpathological ovary specimens obtained from patients undergoing surgery for pathologies other than ovarian carcinoma. Origin of the cells was confirmed by immunohistochemistry. All studies were approved by the Institutional Review Board of Istituto Nazionale Tumori.
Mabs MOV18 (IgG 1 ) and MOV19 (IgG 2a ) directed to FR, 9, 36 MINT5 and MGR6 directed, respectively, against HER-1 and HER-2 37, 38 and 9E10 (IgG 1 ) directed to a myc sequence 39 present in the C-terminus of scFv protein were affinity-purified from hybridoma supernatants on protein A-Sepharose Cl-4B (Pharmacia Biotech).
Integrin expression was tested using a kit of antibodies directed against a and b subunits (Chemicon International, Inc., Temecula, CA, USA). Laminin was detected using a commercial Mab (Sigma).
Vector construction and transfection
We showed previously that the MOV19 scFv antibody expressed in the periplasm of E. coli or at the surface of filamentous phage retains the immunologic specificity and affinity of the intact antibody for FR. 40 For expression of scFvMOV19 or an irrelevant scFv and their retention in the ER, 41 we used the vector scFvE-er 42 (kindly provided by A Brudberry, SISSA, Trieste, Italy) in which the EF BOS promoter is replaced by the weaker cytomegalovirus (CMV) promoter. scFv was inserted as a PstI/NotI fragment to generate the vector MOV19 scFvEerCMV. Cells were transfected with Lipofectin essentially as suggested by the manufacturer (Gibco BRL). Briefly, 10 5 cells were seeded in six-well plates 1 day before transfection at a density resulting in 40-50% confluence, the day of transfection. Prior to transfection, cells were washed once with phosphate-buffered saline (PBS), and 3 ml of fresh standard medium without FCS was added. Supercoiled DNA (5 mg) from MOV19scFvE-erCMV, irrelevant-scFvE-erCMV or empty vector was used for transfection. The mixture was added dropwise to the cells followed by overnight incubation at 371 in a 5% CO 2 atmosphere. After about 18 h, the medium was replaced with fresh standard medium. Transiently transfected cells were tested 48 h later by FACS, whereas stably transfected clones were selected in G418 (Gibco BRL) (400 mg/ml) and tested approximately 15 days later. For IGROV1 cells, the polyclonal transfected populations and, as control, the parental cells were subcloned at limiting dilution (1 cell/well) to obtain single clones.
FACS analysis
Primary antibody (10 mg/ml) was added to human tumor cells (3 Â 10 5 ) in 100 ml PBS 1% bovine serum albumin, and the mixture was incubated for 30 min at room temperature. Antibody binding was detected by a fluoresceinisothiocyanate (FITC)-conjugated secondary antibody (Sigma) for 30 min on ice. For each sample, 5000 cells were analyzed with a FACscan (Becton Dickinson) using Lysys II software. The fluorescence index (FI) was calculated as the ratio between mean fluorescence intensity in the presence and absence of primary antibody.
Protein preparation, SDS-PAGE and Western immunoblotting
To detect FR, cell lysate preparation and immunoblotting were performed essentially as described. 19 To detect scFv, cells were solubilized in sample buffer and 50 mg of total lysate was loaded on 10% gel and the supernatant of ibridoma 9E10 was used diluted 1:5 in blotto. Reaction was developed by ECL-plus (Amersham). To evaluate laminin deposition, parental cells and transfectants were grown for 3 days until confluent and removed by procedures that leave behind functional extracellular matrix. 43 Matrix was solubilized in sample buffer, separated by SDS-PAGE on a 7.5% gel, transferred to nitrocellulose, and blotted as described. 19 
RT-PCR
Transfected clones and parental cell lines were tested for mRNA expression by RT-PCR. RNA was isolated from 5 Â 10 6 cells using the Rneasy total RNA kit (Qiagen, Hilden, Germany). RNA (2 mg) was reverse-transcribed using Moloney murine leukemia virus reverse transcriptase and oligo(dT) primers according to the manufacturer's instructions (GeneAmp, Perkin-Elmer). The cDNA strand generated was used for PCR amplification in a total volume of 20 ml. Samples were amplified at 951C for 3 min, followed by 30 cycles at 951C for 1 min, 581C for 1 min and 721C for 2 min, with a final cycle at 721C for 10 min, in an automated DNA Thermal Cycler (MJ Research, Inc., Watertown, MA, USA). The following primers were used to detect the presence of the intrabody: ScFv5 0 SfiINcoI, CCC AGC CGG CCA TGG CC; and scFv3 0 NotI, TTC TGC GGC CGC CCG TTT. 
Cell growth assays
For in vitro analysis, wild-type, empty vector-transfected (mock), irrelevant-scFv-transfected (irrelevant) or MOV19scFv-transfected IGROV1 cells were briefly (2-3 days) grown in folate-depleted medium (RPMI-1640 folic acid-free) supplemented with 10% FCS and seeded at a density of 10 5 cells/well in six-well plates. Cells were harvested and counted based on trypan blue staining after 4 and 7 days. The same experiments were performed using plates precoated with Matrigel (Biocoat, Collaborative Biomedical Products, Bedford, MA, USA).
For soft agar growth, 2 Â 10 4 cells plated in triplicate in six-well plates were resuspended in 0.33% soft agar (Acumedia, Baltimore, MD, USA), layered onto 1% agar, and continuously grown for 20 days. Agar was supplemented with standard medium.
Cell adhesion assay
Tissue culture plates (24-well) were coated with Matrigel (100 mg/ml) or laminin (50 mg/ml) (Sigma). Cells were seeded at 5 Â 10 4 in standard medium on uncoated or coated plates. After 2 h, unattached cells were removed by serial washings with PBS and attached cells were fixed in 20% methanol and detected with 0.5% crystal violet in 20% methanol. Plates were evaluated on a microplate ELISA reader (Biorad) at 595 nm. All assays were performed in triplicate.
Organotypic cultures and histochemistry
Organotypic cultures were generated essentially as described 44 using 4 Â 10 5 wild-type and transfected cells. The culture medium was HAM-F12 mixed 1:2 with Dulbecco's modified Eagle medium (final content of folic acid isB7 Â 10 3 nM) supplemented with 0.5 mg/ml hydrocortisone (Sigma), 10 ng/ml epidermal growth factor (Sigma), 10% FCS, 2 mM glutamine and 100 mg/ml streptomycin. After 10 days of growth at the air-liquid interface, cells of replicate cultures were fixed in formalin and embedded in paraffin. Sections from the paraffinembedded blocks (5 mm thick) were stained with hematoxylin-eosin for histologic evaluation.
Statistical analysis
In vitro growth and adhesion assays were repeated at least twice under similar conditions and the results obtained were superimposable. The data reported refer to a single experiment and represent the mean and s.d. of replicates. Unpaired two-sided Student's t-tests were used to determine the statistical significance of the intrabody effect. P-values of less than 0.05 were considered significant. Pearson's correlation analysis and linear regression were used to evaluate the relation between FR downmodulation and transfectant proliferation or adhesion, respectively. All statistical analyses were carried out with the GraphPad-PRISM software package (Version 3).
